Laura A. Strom
CURRICULUM VITAE
LAURA A. STROM, MD
ASSOCIATE PROFESSOR, DEPARTMENT OF NEUROLOGY
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS
Office Address: Department of Neurology
University of Colorado Anschutz Medical Campus
Mail Stop F-727, 1635 Aurora Court
Aurora, Colorado 80045
Phone: 720-848-2080
Fax: 720-848-2106
EDUCATION/TRAINING
1988‑1993 B.A., Chemistry, California State University
1993‑1997 M.D., Pennsylvania State University, College of Medicine
1997‑1998 Internship, (Psychiatry) Pennsylvania State University, College of Medicine
1998‑1999 Internship, (Medicine) University of CO, Health Sciences Center
1999-2002 Resident, (Neurology) University of CO, Health Sciences Center
2002-2004 Post doctoral fellowship (Epilepsy) University of CO Health Sciences Center
2004-2008 Clinical Science Research Training
2014-2015 Institute for Healthcare Quality, Safety and Efficiency - certificate training
FACULTY APPOINTMENTS
2004-2008 Instructor – Neurology, University of CO, Denver
2008‑2014 Assistant Professor of Neurology, University of CO, Denver
2014 - Present Associate Professor of Neurology, University of CO, Denver
MAJOR COMMITTEE AND SERVICE RESPONSIBILITIES
Department of Neurology
2008-Present Neurology Clinic, Practice Director
2008 – Present Neurosciences Strategic Planning Committee
2010 – Present co-chair, Clinical Affairs Task Force
2010 – 2012 member, University of Colorado School of Medicine Faculty Senate
2011 – Present Incentive Committee
2012 – Present Section Chief – Neurology Faculty Practice
2013 – Present Neurology Executive Committee
2013 – Present Neurology Performance Improvement Committee
University of Colorado, School of Medicine
2011 – Present Finance and Audit committee
University of Colorado Hospital
2008 – Present Practice Operations Management Committee
2009-2010 Vision 2020 Committee
2009-2011 Tower Expansion Project Committee
2014-Present Adult Clinical Operations Committee
Community and National
2002 – 2010 Adams County, SUDEP task force
2005 – Present member, Physician’s Advisory Board, Epilepsy Foundation
2009 CME committee, American Clinical Neurophysiology Society
2009 – 2010 chair elect, Physician’s Advisory Board Epilepsy Foundation
2010 – 2011 past chair, Physician’s Advisory Board Epilepsy Foundation
2010 – 2012 Membership Committee, American Epilepsy Society (AES)
2010 – 2014 Web development Committee, AES
2013 – 2015 Chair, Neuropharmacology Special Interest Group, AES
AWARDS AND HONORS
1992 Outstanding Chemistry Graduate, California State University, Fresno
1997 Roche Award for Clinical Excellence, Penn State, College of Medicine
2013 Listed in “Best Doctors in America 2013” preeminent database
2013 President’s Award, University of Colorado Hospital
2015, 2016 Castle Connolly Top Doctor in Neurology
MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES
American Academy of Neurology member since 1999
American Epilepsy Society (AES) member since 2001
American Clinical Neurophysiology Society (ACNS) member since 2008
Center for Neuro-Science, University of Colorado, Denver member since 2011
MEDICAL BOARD CERTIFICATION
American Board of Psychiatry and Neurology, 2007
American Board of Psychiatry and Neurology, Certification in Epilepsy 2013
CURRENT LICENSURE
State of Colorado Active
DEA Active
CLINICAL ACTIVITIES
Protocol development for administration of Intracarotid Amytal Testing in Deaf patients
INVITED LECTURES AND PRESENTATIONS (local and regional):
PML, Case Review. Invited Speaker. Neurology Grand Rounds, UCD. May 2002
Ictal Fear. Invited Speaker. Neurology Grand Rounds, UCD. March 2003
Periventricular Nodular Heterotopia, Invited Speaker. Neurology Grand Rounds, UCD. August 2006
EEG in the ICU: Current trends and the UCH experience. Invited Speaker. Neurology Grand Rounds, UCD. October 2007
Differential Diagnosis of Spells; Physiologic & Psychogenic. Invited Lecturer, Resident Lecture Series August 2010
EEG in the ICU Update, Invited Speaker. Neurology Grand Rounds, UCD. September 2009
Cooling the Brain: EEG in the CICU Invited Speaker. Neurology Grand Rounds, UCD. August 2011
Disrobing & Epilepsy, Invited Participant Speaker, Behavior Neurology and Neuropsychiatry conference series June 2011
Cooling the Brain: EEG in the CICU, Invited Speaker, Neurology Grand Rounds, UCD August 2011
Neurology Outpatient Clinic: Quality Improvement. Invited lecturer, University Hardwiring Excellence Series. February 2012
Depression in Epilepsy, the deranged limbic system. March 2013
Seizures and other paroxysmal events: EMS Fridays., Department of Neurology Resident Lecture Series. November 2013
Treatment Options for People with Intractable Temporal Lobe Epilepsy, Invited Speaker, Neurology Grand Rounds, UCD July 2013 2013
Updates in Therapy for Drug-resistant Epilepsy, Invited Speaker, Neurology Grand Rounds, UCD August 2013
Acute Management of Seizures in the Outpatient Setting, Invited lecturer, Department of Integrative Medicine, September 2013
New and Emerging Therapies for Drug Resistant Epilepsy Invited speaker, Department of Neurology CME event – Epilepsy and Non-Parkinson Movement Disorders – 2013. September 2013
Current Controversies in Epilepsy Care: A Debate, Invited Speaker, Neurology Grand Rounds, UCD January 2014
Who Ya Gonna Call? Resident Phone Triage, Invited Speaker, Neurology Grand Rounds, UCD April 2014
Differential Diagnosis of Spells; Physiologic & Psychogenic. Invited Lecturer, Epilepsy Fellows Lecture Series. September 2014
Neurology CME event – Epilepsy and Stroke 2014. Status Epilepticus – Seizure ClustersTreatment. October 2014
Medication Discontinuation Post Epilepsy Surgery: a Debate. December 2014 American Epilepsy Society.
Differential Diagnosis of Spells; Physiologic & Psychogenic. Invited Lecturer, Epilepsy Fellows Lecture Series. September 2015
TEACHING SERVICE Ward/Clinic Attending Duties:
2005 – present core Curriculum Series, Neurology Residency Training Program, UCD
2009 – 2011 annual 2 week inpatient neurology service attending MD with one senior resident and two junior residents, one psychiatry resident and 3-4 medical students
2005 – Present 10 - 12 times per year – 1 week inpatient epilepsy monitoring unit attending physician supervising one fellow and one resident and 1 medical student
2005 – Present 10 - 12 times per year – 1 week inpatient neuro-ICU EEG monitoring attending supervising one fellow
2010 – 2012 Clinical preceptor, MSTP Foundations of Doctoring course
OTHER SPECIFIC ACCOMPLISHMENTS – NEUROLOGY DEPARTMENT & SCHOOL OF MEDICINE (SOM), UCD
2007 – 2008 faculty research mentor – Dr. Danielle McDermott
2007 – 2010 Faculty resident mentor – Dr. Jocelyn Bear
2012 – 2015 Faculty resident mentor – Dr. Taylor Finseth
2010 – 2012 Faculty mentored scholarly activity – Richard Kemp SOM, UCD
2011 – 2013 Faculty mentored scholarly activity – Ryan Barmore SOM, UCD
2012 – 2013 Faculty research mentor – Dr. Stephanie Dunlap (school of Pharmacy)
2014 – present Faculty mentor for junior faculty Dr. Jean Tsai (Dept of Neurology)
GRANTS/OTHER FUNDING
Nordic Fund – Thor Berg Fund in Neurology = $50,000 (current payout)
This is an unrestricted private donation utilized currently for professional research assistant salary support. Future funding will support a neurology indigent care clinic at the Metro Community Provider Network clinic site in Aurora, Colorado.
CURRENT RESEARCH SUPPORT
5/28/14-Ongoing
Principal Investigator
USL P261-408: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects with Seizure Clusters
Direct cost per patient: $11,698
Length of Study: Until the drug is approved
11/15/2012-Ongoing
Principal Investigator
USL P261-402: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters
Direct cost per patient: $9445
Length of study: Until drug is approved
1/02/14-2015
Principal Investigator
Marinus 1042-0603: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment
Direct cost per patient: $9950
Length of study: 9 months
11/19/13-2016
Principal Investigator
UCB Biosciences 1379: An Open-Label, Multicenter, Follow-Up Study to evaluate the long-term safety and efficacy of Brivaracetam used as adjunctive treatment in subjects aged 16 years or older with epilepsy
Direct Cost per patient: $11,939
7/09/2013-2016
Principal Investigator
UCB Biosciences 1358: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of Brivaracetam in subjects with partial onset seizures
Direct Cost per patient: $11,939
1/1/12-Ongoing
Principal Investigator
USL P261-401: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-1
Direct cost per patient: $9445
Length of study: 6 months, dependent upon first seizure cluster after randomization
3/03/11 – 6/27/12
Principal Investigator
UCB SP0962 study: An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated with Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy
Direct costs: $6337 (per patient for entire study)
Enrollment: 1 patient
Length of study: 56 weeks
7/07/11-2016
Principal Investigator
Sunovion BIA-2093-304 study: Efficacy and safety of eslicarbazabine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in a double-blind, randomized, placebo-controlled parallel-group, multicenter clinical trial
Direct costs: $14344 (per patient for entire study)
Enrollment: 3 patients
Length of study: 41 months
3/03/11 – 01/10/12
Principal Investigator
UCB SP0961, An open-label pilot study to assess the safety of oral lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy
Direct costs: $7878 (per patient for entire study)
Enrollment: 3 patients
Length of study: 24 months
11/30/09 – 2016
Principal Investigator
Sunovion, 093-050 study; Long-Term Eslicarbazepine Acetate Extension Study
Direct costs: $7314 (per patient for entire study)
Enrollment: 2 patients at $7314 each = $14,628
Length of study: 36 mos.
12/23/09 – 05/17/12
Principal Investigator
Supernus Prosper 302 study: Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Three Concomitant Antiepileptic Medications
Direct costs: $5270 (per patient for entire study)
Indirect costs: $1370
Enrollment: 4 patients at $5270 each = $21,080
Length of study: 14 mos.
12/10/09 – 10/14/11
Principal Investigator
Supernus Prosper 301 study: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Three Concomitant Antiepileptic Medications
Direct costs: $8620 (per patient for entire study)
Indirect costs: $2241
Enrollment: 4 patients at $8620 each = $34,480
Length of study: 8-9 mos.
11/06/09 – 08/29/13
Principal Investigator
Sunovion 093-045 study: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Direct costs: $12030 (per patient for entire study)
Indirect costs: $3027
Enrollment: 3 patients at $12030 each = $36,090
Length of study: 2 yrs.
01/31/08 – 01/15/10
Principal Investigator
Marinus Pharmaceuticals, Inc, Research 1042-0601 study; an open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures.
01/31/08 – 02/25/09
Principal Investigator
Marinus Pharmaceuticals, Inc, Research 1042-0600 study; A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures.
BIBLIOGRAPHY
PEER REVIEWED ARTICLES
1. Strom, L.A., Anderson J.R., J.R. Gandler. Journal of Chemical Education 69 (7): 588. The Synthesis of E-Beta-bromostyrene – an experiment illustrating the use of IR bending modes to distinguish E-isomers and Z-isomers and the concept of kinetic and thermodynamic controlled reactions.
2. Frey LC, Strom LA, Shrestha A, Spitz MC. End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. Epilepsy Behav. 2009 Aug;15(4):521-3.
3. Laura A. Strom, Susan Koh, Lauren Frey. New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin. Current Treatment Options in Neurology. 2010 12:287–299DOI 10.1007/s11940-010-0079-4
4. Wortzel, H. S., Strom, L. A., Anderson, A. C., Maa, E. H. and Spitz, M. (2012), Disrobing Associated with Epileptic Seizures and Forensic Implications. Journal of Forensic Sciences, 57: 550–552. doi: 10.1111/j.1556-4029.2011.01995.
BOOK CHAPTERS
Fenton, Lynne; Rothberg, Brian; Strom, Laura; Heru, Alison; Brown, Mesha Gay. Integrative Care Model for Neurology and Psychiatry: Non-Epileptic Seizures Project, In: Psychiatry, Primary Care, and Medical Specialties: pathways for Integrated Care. Oxford University Press; (in press)
Spitz MC, Strom LA. , Diagnostic and localizing intracranial EEG features of epileptic seizures, In: Epilepsy and intensive care monitoring: principles and practice. Bruce Fisch, MD, ed., Demos Medical Pub.; 2010.
ABSTRACTS
1. Spitz, M.C., Frey, L.C., Strom, L.A., Shrestha, A., Patz, M.D.: Risk factors influencing the development and prognosis of mania following anterior temporal lobectomy. Epilepsia, 46 (S8):247. (2005)
2. Frey, L.C., Strom, L.A., Shrestha, A., Spitz, M.C.: Withdrawal symptoms associated with lamotrigine use. American Epilepsy Society Abstract 2.114.(2006)
3. Shrestha, A., Frey, L.C., Maa, E., Strom, L.A., Spitz, M.C.: Lamotrigine and late onset rash. American Epilepsy Society Abstract 2.159.(2006)
4. Spitz, M.C., Anderson, C.A., Wortzel, H.S., Maa, E. H., Strom, L.A.: Disrobing in Epilepsy. American Epilepsy Society Abstract 1.040.(2007)
5. Strom, L.A., Hall, D.A., Moon, M., Lederer, M., Pelak, V.S.: Visual Hallucinations and Sleep Disturbances in Parkinson Disease. North American Neuro-Ophthalmology Society (2009)
6. Strom, L.A., Frey, L.C., Spitz, M.C.: Continuous EEG Monitoring in a Tertiary Care Facility. American Clinical Neurophysiology Society Abstract. (2009)
7. Spitz, M., Moreland, S., Frey, L., O’Brien, C., Shrestha, A., Strom, L.: Ablative Temporal Lobe Epilepsy Surgery Should be considered in Patients with a Pre-existing liver Transplantation. American Epilepsy Society Abstract 3.125. (2010)
8. McDermott, M., Kemp R., Strom, L.: Recurrence of Seizures in SREAT After Discontinuation of Immunomodulation. American Epilepsy Society Abstract 3.106. (2010)
9. Afra, P., Strom, L., Bainbridge, J., Buchanan, T., Berry, A., Spitz, M.: Role of Lacosamide as Adjunctive Treatment of Adults with Primary Generalized Epilepsy. American Epilepsy Society Abstract 2.159 (2010)
10. K. L. Conger, E. Lampe, C. Wingrove, L. Strom: - Tertiary care experience of the evaluation and management of PNES. American Epilepsy Society Abstract 3.239 (2011)
11. A. Shrestha, C. Livsey, L. Strom: Contribution of Continuous Video-EEG Monitoring for Prognosis During and Following Cooling Protocol after Cardio-Pulmonary Arrest. American Epilepsy Society Abstract 1.200 (2011)
12. McDermott D, Strom L, Frey L. Presurgical evaluation of epilepsy surgery in adult patients with Tuberous Sclerosis Complex. American Epilepsy Society Abstract 3.289. (2012)
13. K Horiuchi, K Lervik, S Pearson, C Drees, L Strom: Incidence of ezogabine side effects and implementation of a safety protocol. American Epilepsy Society Abstract (2013)
14. Dunlap S, K Lervik, Bainbridge J, Strom L: Objective Self-Measurement of the Subjective Side Effect of Dizziness on Sodium channel Blocking AEDs. American Epilepsy Society Abstract 2.150 (2013)
15. Danielle McDermott, Laura Strom, Cornelia Drees. Improving Time to Treatment and Resolution of Status Epilepticus. American Epilepsy Society Abstract 3.153 (2013)
16. Joanne Rogin, Andrew Cole, Laura Strom, Julie Passarell, Jill Fiedler-Kelly, Elizabeth Ludwig, David Blum and Soujanya Sunkaraneni. Relationship Between Exposure and Efficacy of Eslicarbazepine Acetate Monotherapy. American Epilepsy Society Abstract 1.314 (2014)
17. Cornelia Drees, Rhonda DeBello, Lauren Frey, Pearce Korb, Archana Shrestha, Laura Strom, Mark Spitz and Chantal O'Brien. Process Improvement to Reduce Time to Epilepsy Surgery. American Epilepsy Society Abstract 2.053 (2014)